Literature DB >> 24707126

Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

Verónica Saludes1, Victoria González1, Ramon Planas1, Lurdes Matas1, Vicente Ausina1, Elisa Martró1.   

Abstract

Hepatitis C virus (HCV) infection represents a major public health issue. Hepatitis C can be cured by therapy, but many infected individuals are unaware of their status. Effective HCV screening, fast diagnosis and characterization, and hepatic fibrosis staging are highly relevant for controlling transmission, treating infected patients and, consequently, avoiding end-stage liver disease. Exposure to HCV can be determined with high sensitivity and specificity with currently available third generation serology assays. Additionally, the use of point-of-care tests can increase HCV screening opportunities. However, active HCV infection must be confirmed by direct diagnosis methods. Additionally, HCV genotyping is required prior to starting any treatment. Increasingly, high-volume clinical laboratories use different types of automated platforms, which have simplified sample processing, reduced hands-on-time, minimized contamination risks and human error and ensured full traceability of results. Significant advances have also been made in the field of fibrosis stage assessment with the development of non-invasive methods, such as imaging techniques and serum-based tests. However, no single test is currently available that is able to completely replace liver biopsy. This review focuses on approved commercial tools used to diagnose HCV infection and the recommended hepatic fibrosis staging tests.

Entities:  

Keywords:  Diagnosis; Hepatic fibrosis staging; Hepatitis C virus; Hepatitis C virus genotyping; Hepatitis C virus-RNA quantification; Real-time polymerase chain reaction; Serology

Mesh:

Substances:

Year:  2014        PMID: 24707126      PMCID: PMC3974510          DOI: 10.3748/wjg.v20.i13.3431

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  91 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Rapid hepatitis C tests: better than the gold standard?

Authors:  Nitika Pant Pai; Kimberly Sollis; Rosanna W Peeling
Journal:  Expert Rev Mol Diagn       Date:  2013-04       Impact factor: 5.225

3.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

4.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

Authors:  Leon A Adams; Max Bulsara; Enrico Rossi; Bastiaan DeBoer; David Speers; Jacob George; James Kench; Geoffrey Farrell; Geoffrey W McCaughan; Gary P Jeffrey
Journal:  Clin Chem       Date:  2005-07-28       Impact factor: 8.327

6.  Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus.

Authors:  Bryce D Smith; Jan Drobeniuc; Amy Jewett; Bernard M Branson; Richard S Garfein; Eyasu Teshale; Saleem Kamili; Cindy M Weinbaum
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

7.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.

Authors:  J Foucher; E Chanteloup; J Vergniol; L Castéra; B Le Bail; X Adhoute; J Bertet; P Couzigou; V de Lédinghen
Journal:  Gut       Date:  2005-07-14       Impact factor: 23.059

8.  A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen.

Authors:  Kaori Morota; Ryo Fujinami; Hideki Kinukawa; Taiji Machida; Kenichi Ohno; Haruhisa Saegusa; Katsumichi Takeda
Journal:  J Virol Methods       Date:  2009-01-20       Impact factor: 2.014

9.  Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.

Authors:  Maria Buti; Claudia Mendez; Melanie Schaper; Silvia Sauleda; Auristela Valdes; Francisco Rodriguez-Frias; Rosendo Jardi; Rafael Esteban
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

10.  A meta-analysis of transient elastography for the detection of hepatic fibrosis.

Authors:  Justin Stebbing; Lavanta Farouk; George Panos; Mike Anderson; Long R Jiao; Sundhiya Mandalia; Mark Bower; Brian Gazzard; Mark Nelson
Journal:  J Clin Gastroenterol       Date:  2010-03       Impact factor: 3.062

View more
  13 in total

1.  Assessment of fibrotic tissue and microvascular architecture by in-line phase-contrast imaging in a mouse model of liver fibrosis.

Authors:  Yi Fu; Hao-Jie Peng; Xi Zhang; Wei-Jun Peng; Jiong Wu; Sheng-Ping Wang; Min Du; Rui-Min Li
Journal:  Eur Radiol       Date:  2016-01-19       Impact factor: 5.315

2.  Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection.

Authors:  Geneviève Cadieux; Jennifer Campbell; Nandini Dendukuri
Journal:  CMAJ Open       Date:  2016-12-02

Review 3.  Hepatitis C virus: Virology, diagnosis and treatment.

Authors:  Hui-Chun Li; Shih-Yen Lo
Journal:  World J Hepatol       Date:  2015-06-08

Review 4.  Update on hepatitis B and C virus diagnosis.

Authors:  Livia Melo Villar; Helena Medina Cruz; Jakeline Ribeiro Barbosa; Cristianne Sousa Bezerra; Moyra Machado Portilho; Letícia de Paula Scalioni
Journal:  World J Virol       Date:  2015-11-12

5.  Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C.

Authors:  Bo Liu; Ying Xiang; Heng-Shu Zhang
Journal:  Mol Med Rep       Date:  2015-02-24       Impact factor: 2.952

6.  Whole-organ and segmental stiffness measured with liver magnetic resonance elastography in healthy adults: significance of the region of interest.

Authors:  Grażyna Rusak; Elżbieta Zawada; Adam Lemanowicz; Zbigniew Serafin
Journal:  Abdom Imaging       Date:  2015-04

Review 7.  MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations.

Authors:  Jennifer Louten; Michael Beach; Kristina Palermino; Maria Weeks; Gabrielle Holenstein
Journal:  Biomark Insights       Date:  2016-01-18

8.  Molecular characterization of Hepatitis C virus 3a in Peshawar.

Authors:  Amina Gul; Nabeela Zahid; Jawad Ahmed; Fazli Zahir; Imtiaz Ali Khan; Ijaz Ali
Journal:  BMC Infect Dis       Date:  2016-04-18       Impact factor: 3.090

9.  Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India.

Authors:  Sunil S Solomon; Aylur K Srikrishnan; Allison M McFall; M Suresh Kumar; Shanmugam Saravanan; Pachamuthu Balakrishnan; Suniti Solomon; David L Thomas; Mark S Sulkowski; Shruti H Mehta
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

10.  Liver histology in asymptomatic Hepatitis-C virus positive blood donors.

Authors:  Muhammad Anwar; Qamar Jamal; Waqaruddin Ahmed
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.